Form 4: Verona Pharma Director Lisa Deschamps Awarded 96,000 Restricted Share Units

Director Lisa Deschamps received 96,000 Restricted Share Units (RSUs) convertible to American Depositary Shares (ADSs) in Verona Pharma plc on April 25, 2025, according to a Form 4 filing.

Summary

• Lisa Deschamps, a director of Verona Pharma plc, was granted 96,000 Restricted Share Units (RSUs) on April 25, 2025.
• Each RSU represents the right to receive one American Depositary Share (ADS), and each ADS represents eight Ordinary Shares of Verona Pharma.
• The RSUs vest in four equal installments of 25% each on August 1, 2025, November 1, 2025, February 1, 2026, and May 1, 2026, contingent upon continued service to the Issuer.
• The reporting person has direct ownership of the derivative securities.
• The RSUs have no expiration date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs is a standard practice and indicates confidence in the director's continued service and the company's future prospects. There are no immediate negative implications.

Positives

• The award of RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The value of the RSUs is dependent on the future performance of Verona Pharma's stock price, which is subject to market risks and company-specific factors.

Future Outlook

The vesting of the RSUs is contingent upon the director's continued service to the company, suggesting an expectation of ongoing contributions.

Industry Context

Granting stock-based compensation to directors is a common practice in the pharmaceutical industry to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock options and restricted stock units are frequently used in the pharmaceutical industry to compensate executives and directors.
• Companies like AstraZeneca, GlaxoSmithKline, and Novartis also utilize equity-based compensation plans to attract and retain talent.
• The vesting schedule of these RSUs is fairly standard, with quarterly vesting over a one-year period being a common practice.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns the director's interests with their own.
• The director is incentivized to contribute to the company's success to realize the value of the RSUs.

Key Dates

Keywords

Verona Pharma, Restricted Share Units, RSUs, Director, Lisa Deschamps, Form 4, Beneficial Ownership, ADS, American Depositary Shares, Vesting